{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:03Z","timestamp":1790092323499,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymthe.2025.06.031","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:29:04Z","timestamp":1751426944000},"page":"4216-4225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-3828","authenticated-orcid":false,"given":"Sarah P.","family":"Sherlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara G.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Delnomdedieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin K.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7189","authenticated-orcid":false,"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.06.031_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.06.031_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.06.00004906","article-title":"Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients","volume":"28","author":"Toussaint","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2025.06.031_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.amjmed.2004.03.028","article-title":"A new lease on life for patients with Duchenne muscular dystrophy in Japan","volume":"117","author":"Yasuma","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymthe.2025.06.031_bib6","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.031_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.06.031_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.06.031_bib9","series-title":"Paper Presented at the American Society of Gene & Cell Therapy (ASGCT) Immune Responses to Gene Therapies for MusculoSkeletal and Cardiac Diseases Washington DC","article-title":"Extended results from first-in-human clinical trial of RP-A501 (AAV9:LAMP2B) gene therapy treatment for Danon disease","author":"Greenberg","year":"2022"},{"key":"10.1016\/j.ymthe.2025.06.031_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040820","article-title":"Innovative therapeutic approaches for Duchenne muscular dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.06.031_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","article-title":"Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing","volume":"134","author":"Domm","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.06.031_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.031_bib14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.031_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.omtm.2023.05.017","article-title":"Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy","volume":"30","author":"Le Guiner","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.06.031_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jcp.2003.015420","article-title":"Cardiac troponins","volume":"57","author":"Sharma","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib17","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000001001","article-title":"Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association","volume":"144","author":"Law","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.06.031_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","article-title":"Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy","volume":"30","author":"Wagner","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.06.031_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00246-020-02372-5","article-title":"Troponin I levels correlate with cardiac MR LGE and native T1 values in Duchenne muscular dystrophy cardiomyopathy and identify early disease progression","volume":"41","author":"Voleti","year":"2020","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001592","article-title":"Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy Expert Panel","volume":"8","author":"Spurney","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.ymthe.2025.06.031_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/bmm-2021-0222","article-title":"Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial","volume":"15","author":"Wagner","year":"2021","journal-title":"Biomark. Med."},{"key":"10.1016\/j.ymthe.2025.06.031_bib22","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2016.02.081","article-title":"Dystrophin-deficient cardiomyopathy","volume":"67","author":"Kamdar","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11897-020-00456-0","article-title":"Duchenne muscular dystrophy: the heart of the matter","volume":"17","author":"Shih","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.ymthe.2025.06.031_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mus.27522","article-title":"Serum cardiac troponin I is a candidate biomarker for cardiomyopathy in Duchenne and Becker muscular dystrophies","volume":"65","author":"Yamaguchi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.06.031_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting Report: 2022 Muscular Dystrophy Association Summit on safety and challenges in gene transfer therapy","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.06.031_bib26","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.06.031_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary leak syndrome: etiologies, pathophysiology, and management","volume":"92","author":"Siddall","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2025.06.031_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","author":"Butterfield RJ","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.06.031_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.06.031_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12872-022-02688-5","article-title":"Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging","volume":"22","author":"Batra","year":"2022","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ymthe.2025.06.031_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S1047951119002610","article-title":"Left ventricular dysfunction in Duchenne muscular dystrophy","volume":"30","author":"James","year":"2020","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymthe.2025.06.031_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001338","article-title":"Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy","volume":"4","author":"Tandon","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2025.06.031_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.13405","article-title":"Prevalence of cardiac disease in Duchenne muscular dystrophy patients by age: a cardiac magnetic resonance natural history study","volume":"144","author":"Lao","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.06.031_bib34","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.06.031_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.06.031_bib37","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin immunity after gene therapy for Duchenne's muscular dystrophy","volume":"388","author":"B\u00f6nnemann","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625004824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:26:06Z","timestamp":1782505566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625004824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525001625004824"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.031","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}